Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN
RegulatoryapprovedFabhaltaPositive
AI Analysis
Summary
Novartis announced FDA traditional approval of Fabhalta (iptacopan) for primary IgAN, marking the first and only complement inhibitor demonstrated to significantly slow kidney function decline in this indication.
Outcome Details
FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN
Importance:9/10
Sentiment:
0.95
FDA approvalFabhaltaiptacopanIgANcomplement inhibitorkidney diseasefirst-in-class
Related Companies
Read the original article
Published by yahoo_finance on July 16, 2026 11:02 PM